%0 Journal Article
%A Argüelles-Arias, F
%A Guerra Veloz, M F
%A Perea Amarillo, R
%A Vilches-Arenas, A
%A Castro Laria, L
%A Maldonado Pérez, B
%A Chaaro, D
%A Benítez Roldán, A
%A Merino, V
%A Ramírez, G
%A Caunedo Álvarez, A
%A Romero Gómez, M
%T Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
%D 2017
%U http://hdl.handle.net/10668/10954
%X CT-P13 is a biosimilar of Remicade®, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice. This is a prospective observational study in patients with moderate to severe Crohn's disease or ulcerative colitis treated with CT-P13. The study was performed in one single center. Patients included were naive or switched to anti-TNF treatment from the reference infliximab (Remicade®) to CT-P13. Efficacy and safety were assessed in naive and switched patients who were in remission at the time of the switch at months 3 and 6 of therapy. 87.5 and 83.9% of switched CD patients who were in remission at the time of the switch continued in remission, and 66.7 and 50% of naive CD patients reached remission, at months 3 and 6. In UC switched cases, 92 and 91.3% of patients in remission at the time of the switch continued in remission, at 3 and 6 months. In naive UC patients, the remission rates were 44.4 and 66.7%, at months 3 and 6. Adverse events occurred in 7.5% of patients during 6 months of study. CT-P13 was efficacious and well tolerated in patients with CD or UC.
%K Biosimilar agent
%K CT-P13
%K Crohn’s disease
%K Infliximab
%K Ulcerative colitis
%~